BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19064401)

  • 1. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
    Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
    Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
    Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of CHOP with rituximab for lymphomatoid granulomatosis.
    Oosting-Lenstra SF; van Marwijk Kooy M
    Neth J Med; 2007 Dec; 65(11):442-7. PubMed ID: 18079567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
    Balamuth NJ; Nichols KE; Paessler M; Teachey DT
    J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
    Cooles FA; Jackson GH; Menon G; Isaacs JD
    Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
    [No Abstract]   [Full Text] [Related]  

  • 9. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epstein-Barr virus related B-cell lymphoproliferative disorder complicated with bone marrow fibrosis, which was successfully treated with 2 courses of CHOP regimen].
    Hagihara M; Watanabe S; Suyama T; Sato K
    Rinsho Ketsueki; 2005 Oct; 46(10):1129-35. PubMed ID: 16440776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis.
    Bosman G; Langemeijer SM; Hebeda KM; Raemaekers JM; Pickkers P; van der Velden WJ
    Neth J Med; 2009 Sep; 67(8):364-5. PubMed ID: 19767670
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
    Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
    Jäger G; Quehenberger F; Linkesch W; Neumeister P
    Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic trials for a rabbit model of EBV-associated Hemophagocytic Syndrome (HPS): effects of vidarabine or CHOP, and development of Herpesvirus papio (HVP)-negative lymphomas surrounded by HVP-infected lymphoproliferative disease.
    Hayashi K; Joko H; Koirala TR; Onoda S; Jin ZS; Munemasa M; Ohara N; Oda W; Tanaka T; Oka T; Kondo E; Yoshino T; Takahashi K; Yamada M; Akagi T
    Histol Histopathol; 2003 Oct; 18(4):1155-68. PubMed ID: 12973684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effective treatment for a methotrexate-associated lymphoproliferative disorder with R-CHOP following administration of rituximab].
    Kawakami K; Ito R; Watanabe Y; Goto T
    Rinsho Ketsueki; 2005 Jul; 46(7):517-21. PubMed ID: 16440745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.